慢性HBV感染不同疾病状态治疗策略选择与获益评价

doi:10.3969/j.issn.1672-5069.2023.05.001

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (5): 609-611.doi: 10.3969/j.issn.1672-5069.2023.05.001

• 述评 • 下一篇

慢性HBV感染不同疾病状态治疗策略选择与获益评价

盛秋菊, 窦晓光

110022 沈阳市中国医科大学附属盛京医院/辽宁省病毒性肝炎重点实验室

收稿日期:2023-06-21 出版日期:2023-09-10 发布日期:2023-09-13
通讯作者: 窦晓光,E-mail:guang40@163.com
作者简介:盛秋菊,女,38岁,副教授,副主任医师。E-mail:shengqj@sj-hospital.org

Therapeutic strategies and benefit evaluation in patients with chronic hepatitis B viral infection

Sheng Qiuju, Dou Xiaoguang

Institute of Viral hepatitis Study, Shengjing Hospital, China Medical University, Shenyang 110022, Liaoning Province, China

Received:2023-06-21 Online:2023-09-10 Published:2023-09-13

摘要/Abstract

关键词: 慢性乙型肝炎, 抗病毒治疗, 治疗策略

Key words: Hepatitis B, Antiviral therapy, Treatment strategy

盛秋菊, 窦晓光. 慢性HBV感染不同疾病状态治疗策略选择与获益评价[J]. 实用肝脏病杂志, 2023, 26(5): 609-611.

Sheng Qiuju, Dou Xiaoguang. Therapeutic strategies and benefit evaluation in patients with chronic hepatitis B viral infection[J]. Journal of Practical Hepatology, 2023, 26(5): 609-611.

[1] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版). 实用肝脏病杂志, 2023, 26(3): S18-S39.
[2] Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol, 2008, 48(2): 335-352.
[3] Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology, 2010, 51(2): 435-444.
[4] Duberg AS, Lybeck C, Falt A, et al. Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: a national register study. HepatolCommun, 2022, 6(9): 2418-2430.
[5] Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology, 2017, 66(5):1444-1453.
[6] McMahon BJ, Nolen LD, Snowball M, et al. HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: the hepatitis B Alaska study. Hepatology, 2021, 74(6): 2965-2973.
[7] Campbell C, Wang T, McNaughton AL, et al. Risk factors for the development of hepatocellular carcinoma (HCC)in chronic hepatitis B virus (HBV)infection: a systematic review and meta-analysis. J Viral Hepat, 2021, 28(3): 493-507.
[8] Alshuwaykh O, Daugherty T, Cheung A, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy. HepatolCommun, 2022, 6(11): 3052-3061.
[9] Ferreira G, Stuurman AL, Horsmans Y, et al. Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink. Eur J GastroenterolHepatol, 2020, 32(1): 101-109.
[10] Chayanupatkul M,Omino R, Mittal S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol, 2017, 66(2): 355-362.
[11] Singal AK, Salameh H, Kuo YK, et al. Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther, 2013, 38(2): 98-106.
[12] Russo FP, Zanetto A, Pinto E, et al. Hepatocellular carcinoma in chronic viral hepatitis: where do we stand? Int J Mol Sci, 2022, 23(1): 500.
[13] Choi J,Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol, 2019, 5(1): 30-36.
[14] Qi WQ, Zhang Q, Wang X, et al. Long-term clinical benefit of Peg-IFNα and NAs sequential anti-viral therapy on HBV related HCC. Neoplasma, 2021, 68(1): 200-207.
[15] Li SY, Li H, Xiong YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: a five-year observational cohort study. J Viral Hepat, 2017, 24(Suppl 1): 12-20.
[16] Liang KH, Hsu CW, Chang ML, et al. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis, 2016, 213(6): 966-974.
[17] Ren P, Cao Z, Mo R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther, 2018, 18(10):1085-1094.

慢性HBV感染不同疾病状态治疗策略选择与获益评价

Therapeutic strategies and benefit evaluation in patients with chronic hepatitis B viral infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张丹, 丁洋. 慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择^*[J]. 实用肝脏病杂志, 2023, 26(5): 612-614.
[2]	吴育龙, 庄见齐, 刘志成, 马侠槟. 核苷(酸)类似物治疗慢性乙型肝炎患者血清HBV pgRNA变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 622-625.
[3]	王一卓, 张崴琪, 李红. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者3年随访研究[J]. 实用肝脏病杂志, 2023, 26(5): 626-629.
[4]	郝岸华, 杜忠彩, 周林, 马磊. 慢性乙型肝炎患者肝脏硬度检测和S指数变化及评估肝纤维化程度应用价值探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 630-633.
[5]	刘爱华, 符建, 陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 634-637.
[6]	周克丽, 吕晓丽, 周洋, 龙浩成. 应用肝脏硬度检测联合多普勒超声检测门静脉血流动力学指标评估慢性乙型肝炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 480-483.
[7]	刘莹, 陈东妙, 王从容. 慢性乙型肝炎、乙型肝炎肝硬化和原发性肝癌患者血清腺苷脱氨酶、α-L-岩藻糖苷酶和AFP-L3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(4): 552-555.
[8]	陶贞贞, 王永莉, 孙红艳, 王慧芬. 二维剪切波弹性成像诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 328-331.
[9]	赵景, 何秀波, 谌瑾寰. 肝脏剪切波弹性成像联合GGT/PLT比值诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 332-335.
[10]	张丹蕾, 徐静. 艾米替诺福韦治疗慢性乙型肝炎患者早期疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 336-339.
[11]	郭晓玲, 张耀武, 李梦桃, 张辉. 恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 340-343.
[12]	苏佩华, 宋枚芳, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌[J]. 实用肝脏病杂志, 2023, 26(3): 445-448.
[13]	方慧晶, 朱传龙, 章莉莉. 宿主靶向抗乙型肝炎病毒治疗策略研究新进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 449-452.
[14]	尹雯, 鲁科翔, 王雪, 王彩艳. 恩替卡韦联合苦参素治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 173-176.
[15]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.